Dobrev Dobromir
Department of Pharmacology and Toxicology, Dresden University of Technology, Fetscherstr. 74, 01307 Dresden, Germany.
J Interv Card Electrophysiol. 2008 Aug;22(2):107-10. doi: 10.1007/s10840-007-9195-9. Epub 2008 Mar 11.
Atrial fibrillation is the most frequent cardiac arrhythmia in clinical practice. Although much has been learned, the underlying mechanisms are incompletely understood. Clinically used antiarrhythmic drugs are limited in their efficacy to terminate atrial fibrillation or to maintain sinus rhythm and were associated with substantial toxicity including life-threatening ventricular arrhythmias. Novel therapeutic approaches suggest targeting of atrium-selective ion channels and pathology-specific alterations in atrial repolarisation and arrhythmogenesis as promising drug targets for patients with atrial fibrillation. This article focuses on novel aspects of altered atrial repolarisation and discusses atrium-selective (I(Kur), I(K,ACh)) and pathology-specific (I(K,ACh)) ion channels as potential targets for safe and effective treatment of atrial fibrillation.
心房颤动是临床实践中最常见的心律失常。尽管已经有了很多了解,但其潜在机制仍未完全明了。临床使用的抗心律失常药物在终止心房颤动或维持窦性心律方面疗效有限,且伴有包括危及生命的室性心律失常在内的严重毒性。新的治疗方法表明,针对心房选择性离子通道以及心房复极和心律失常发生过程中的病理特异性改变,有望成为心房颤动患者的药物靶点。本文重点关注心房复极改变的新方面,并讨论心房选择性(I(Kur)、I(K,ACh))和病理特异性(I(K,ACh))离子通道作为安全有效治疗心房颤动的潜在靶点。